Pneumonia antibiotics

Streptococcus faecalis uv disinfection, 8 652t Streptococcus pneumonia antibiotic resistant, 3 36 Streptocyanines, 20 505 Streptokinase, 5 175, 176... 

The trial court, and then the Supreme Court of New Jersey, agreed that Karen s respirator could be removed. So it was disconnected. However, the nurse in charge of her care in the Catholic hospital opposed this decision and, anticipating it, had begun to wean her fi om the respirator so that by the time it was disconnected she could remain alive without it. So Karen did not die. Karen remained aHve for ten additional years. In June 1985, she finally died of acute pneumonia. Antibiotics, which would have fought the pneumonia, were not given. 

Pneumogstis carini pneumonia (PCP), the most common of the opportunistic infections, occurs in more than 80% of AIDS patients (13). Toxoplasmosis, a proto2oan infection of the central nervous system, is activated in AIDS patients when the 004 count drops and severe impairment of ceU-mediated immunity occurs. Typically, patients have a mass lesion(s) in the brain. These mass lesions usually respond well to therapy and can disappear completely. Fungal infections, such as CTyptococcalmeningitis, are extremely common in AIDS patients, and Histop/asma capsulatum appears when ceU-mediated immunity has been destroyed by the HIV vims, leading to widespread infection of the lungs, Hver, spleen, lymph nodes, and bone marrow. AIDS patients are particularly susceptible to bacteremia caused by nontyphoidal strains of Salmonella. Bacteremia may be cleared by using antibiotic therapy. 

As mentioned earlier, a-D-carba-galactopyranose (1) has been found in a fermentation broth of Streptomyces sp. MA-4145, as an antibiotic. The potency of the antibiotic was rather low. A concentration of—125 fig/mh is required in order to produce a standard inhibition zone of 25-mm diameter against Klebsiella pneumoniae MB-1264, using 13-mm assay discs in a disc-plate assay. A sample of the synthetic a-DL-carba-galactopyranose (17) was... 

Deformylation of nascent polypeptides has been shown to be a function essential for growth in E. coli, Staphylococcus aureus and Streptococcus pneumoniae [15-18]. Moreover, antibacterial mode of action studies, using S. pneumoniae or S. aureus strains in which the expression of PDF is controlled by regulatable promoters, have shown that the antibacterial activity of PDF inhibitors is due to their inhibition of the PDF enzyme, as the susceptibility of the strains to these compounds is dependent on the amount of protein present in the cell [19-21]. These results further validate PDF as a target for novel antibiotics. 

Unless risk factors for infection owing to potentially antibiotic-resistant bacteria ° Late-onset hospital-acquired pneumonia... 

Routine antibiotic use is not warranted because the primary infectious agents associated with asthma exacerbations are viruses.2,3 Antibiotics should be reserved for situations when bacterial infection is strongly suspected (e.g., fever and purulent sputum, pneumonia, and suspected sinusitis). 

Uncomplicated exacerbation Not requiring hospitalization Less than 3 exacerbations per year No comorbid illness I I V, greater than 50% predicted No recent antibiotic therapy Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis Oral Macrolide (azithromycin, clarithromycin) Second- or third-generation cephalosporin (cefuroxime, cefpodoxime, cefdinir, cefprozil) Doxycycline Ketolide (telithromycin) P-Lactam/P-Iactamase inhibitor (amoxicillin-clavulanate) Intravenous Not recommended... 

Complicated exacerbation FEV, less than 50% predicted Comorbid cardiac disease Greater than or equal to 3 exacerbations per year Antibiotic therapy in the previous 3 months Above organisms plus drug-resistant pneumococci, P-lactamase-producing H. influenzae and M. catarrhalis, Escherichia coli, Proteus spp., Enterobacter spp., Klebsiella pneumoniae Oral P-Lactam/P-Iactamase inhibitor (amoxicil 1 i n-clavulanate) Fluoroquinolone with enhanced pneumococcal activity (levofloxacin, gemifloxacin, moxifloxacin) Intravenous P-Iactam/P-Iactamase inhibitor (ampicillin-sulbactam) Second- or third-generation cephalosporin (cefuroxime, ceftriaxone) Fluoroquinolone with enhanced pneumococcal activity (levofloxacin, moxifloxacin)... 

Broad intravenous antibiotic coverage for the encapsulated organisms can include ceftriaxone or cefotaxime. For patients with true cephalosporin allergy, clindamycin may be used. If staphylococcal infection is suspected owing to previous history or the patient appears acutely ill, vancomycin should be initiated. Macrolide antibiotics, such as erythromycin and azithromycin, may be initiated if Mycoplasma pneumonia is suspected. While the patient is receiving broad-spectrum antibiotics, their regular use of penicillin for prophylaxis can be suspended. Fever should be controlled with acetaminophen or ibuprofen. Because of the risk of dehydration during infection with fever, increased fluid may be needed.6,27... 

If a patient aspirates his or her oral contents and pneumonia develops, then anaerobes and Streptococcus spp. are the primary pathogens. Antibiotics active against these organisms include penicillin G, ampicillin/sulbactam, clindamycin, and metronidazole. 

The 23-valent pneumococcal polysaccharide vaccine contains 23 serotypes that are responsible for causing more than 80% of invasive S. pneumoniae infections in adults. The vaccine includes those serotypes that are associated with drug resistance. Use of the vaccine will not prevent the development of antibiotic-resistant S. pneumoniae, but is likely to prevent infection from drug-resistant strains. The 23-valent pneumococcal polysaccharide vaccine has demonstrated good immunogenicity in adults, but an individual will not develop immunity to all 23 serotypes following vaccination.10... 

Trimethoprim-sulmethoxazole is started in all patients with acute leukemia for the prevention of Pneumocystis car-rinii pneumonia. Patients normally continue this therapy for 6 months after completion of treatment. The use of additional antibiotic prophylaxis is not encouraged in all patients with leukemia because of concerns for antibiotic resistance. 

A 75- year-old woman is hospitalized for pneumonia and treated with an intravenous antibiotic. On day threet she develops severe diarrhea. Stool is positive for Clostridium difficile toxin What is the best treatment ... 

Patients with documented or suspected SBP should receive broad-spectrum antibiotic therapy to cover Escherichia coliy Klebsiella pneumoniae, and Streptococcus pneumoniae. 

Meningitis caused by S. pneumoniae is successfully treated with 10 to 14 days of antibiotic therapy. Meningitis caused by N. meningitidis usually can be treated with a 7-day course. A longer course, >21 days, is recommended... 

When possible, antibiotic therapy is directed toward anticipated respiratory pathogen(s) (i.e., Streptococcus pneumoniae, Haemophilus influenzae) and/or those demonstrating a predominant growth upon throat culture. 

---